Status:

SUSPENDED

EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms With the Pipeline™ Flex Embolization Device With Shield TEchnology™ (ELEVATE)

Lead Sponsor:

Medtronic Neurovascular Clinical Affairs

Conditions:

Intracranial Aneurysm

Ruptured Aneurysm

Eligibility:

All Genders

22-80 years

Phase:

NA

Brief Summary

The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.

Detailed Description

The ELEVATE study is a prospective, multi-center, single-arm trial of the Pipeline™ Shield Device for the treatment of adults with acutely ruptured intracranial aneurysms. The primary objective of the...

Eligibility Criteria

Inclusion

  • Subject has a previously untreated, wide neck, side-wall, intradural aneurysm that is deemed unfavorable for both surgical clipping and endovascular coiling, as confirmed on DSA.
  • Subject has a ruptured intracranial aneurysm with vessel diameter suitable for treatment with the study device.
  • Subject is ≥ 22 and ≤ 80 years of age.
  • Subject has an acutely ruptured aneurysm with Hunt and Hess Scale 1, 2 or 3.
  • Subject or subject's Legally Authorized Representative (LAR) has provided written informed consent.

Exclusion

  • Subject's vessel characteristics preclude safe endovascular access to the aneurysm to treat with the Pipeline™ Shield Device.
  • Subject has aneurysm vessel characteristics that would preclude the device from fully conforming to the parent vessel to reduce any risk of embolic complications, retreatment, or device movement.
  • Subject has true bifurcation or aneurysms with vessels that cannot be separated from the fundus with placement of the study device.
  • Subject with intraparenchymal hemorrhage.
  • Subject is unable to undergo nasogastric/orogastric tube placement prior to device placement.
  • Subject has a pre-morbid mRS \>2.
  • Subject requires treatment of another aneurysm (with another treatment modality) within the affected territory of the target aneurysm.
  • Subject has a target ruptured aneurysm that is thought to be mycotic, including those caused by left atrial myxoma, or subject has an active systemic bacterial infection.
  • Subject with a requirement for continuous anti-coagulation.
  • Subject has a malignant brain tumor or vascular malformation (e.g. arteriovenous malformation).
  • Subject's target ruptured aneurysm has not been determined by the treating physician to be the source of SAH.
  • Subject with known allergy to platinum or cobalt chromium alloy (including the major elements platinum, cobalt, chromium, nickel or molybdenum).
  • Subject has a known hypersensitivity to ticagrelor or aspirin.
  • Subject is unable to undergo DSA or DSA is determined unsuitable by the treating physician.
  • Subject has a serious or life-threatening comorbidity that could confound study results.
  • Subject is at high risk of noncompliance per treating physician due to reasons including but not limited to a history of substance abuse.
  • Subject is unable to complete scheduled follow-up assessments due to comorbidities, geographical limitations, or a life expectancy of less than 24 months.
  • Subject is pregnant, or breastfeeding at the time of admission or plans to become pregnant during their participation in the study.
  • Subject is participating in another clinical study at the time of enrollment.
  • Presumed septic embolus, or suspicion of microbial superinfection.
  • Subject with a known COVID-19 viral infection, confirmed by testing.
  • Subject in whom a pre-existing stent is in place in the parent artery at target aneurysm location.

Key Trial Info

Start Date :

May 6 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2025

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04391803

Start Date

May 6 2022

End Date

October 1 2025

Last Update

June 6 2025

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

University of Colorado Hospital

Aurora, Colorado, United States, 80045

2

Swedish Medical Center

Englewood, Colorado, United States, 80113

3

Yale New Haven Hospital

New Haven, Connecticut, United States, 06510

4

Baptist Medical Center Jacksonville

Jacksonville, Florida, United States, 32207